Some Principles Related to Chemogenomics in Compound Library and Template Design for GPCRs

Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective

Volumn , Issue , 2005, Pages 311-324

  Webb, Thomas R ^a  

^a ChemBridge Research Laboratories   (United States)

Author keywords

Chemical libraries; Chemogenomics; Chemogenomics in compound libraries; Design of targeted libraries; Template design for GPCRs

Indexed keywords

CHEMICAL LIBRARIES; CHEMOGENOMICS; COMPOUND LIBRARIES; TEMPLATE DESIGNS;

LIBRARIES;

EID: 84954305502     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527603948.ch11     Document Type: Chapter

References (71)

1. K.H. Bleicher, Chemogenomics:bridging a drug discovery gap, Curr. Med.Chem. 2002, 9, 2077-2084.
2. P.R. Caron, M.D. Mullican,R.D. Mashal, K.P. Wilson, M.S. Su,M.A. Murcko, Chemogenomicapproaches to drug discovery. Curr. Opin.Chem. Bio. 2001, 5, 464-470.
3. T. Klabunde, G. Hessler, Drug designstrategies for targeting G-protein-coupledreceptors, ChemBioChem 2002, 3, 928-924.
4. A. Schuffenhauer, P. Floersheim,P. Acklin, E. Jocoby, Similarity metricsfor ligands reflecting the similarity of thetarget protein, J. Chem. Inf. Comp. Sci.2003, 43, 391-405.
5. L.J. Browne, M.L. Furness,G. Natsoulis, C. Pearson, K. Jamagin,Chemogenomics: pharmacologywith genomics tools, Targets 2002, 1,59-65.
6. G.H.S. Ashton, J.A. McGrath,A.P. South, Strategies to identifydisease genes, Drugs of Today 2002, 38,235-244.
7. A. Schuffenhauer, J. Zimmermann,R. Stoop, J.-J. Van der Vyver,S. Lecchini, E. Jacoby, An ontologyfor pharmaceutical ligands and itsapplication for in silico screening andlibrary design, J. Chem. Inf. Comp. Sci.2002, 42, 947-955.
8. X.F.S. Zheng, T.-F. Chan, Chemicalgenomics: a systematic approach inbiological research and drug discovery,Curr. Issues Mol. Bio. 2002, 4, 33-43.
9. Y. Bae, T.G. Lee, J.C. Park, J.H. Hur,Y. Kim, K. Heo, J. Kwak, P. Suh,S.H. Ryu, Identification of a compoundthat directly stimulates phospholipase Cactivity. Molecular Pharmacology 2003, 63,1043-1050.
10. T. Ma, J.R. Thiagarajah, H. Yang,N.D. Sonawane, C. Folli,L.J.V. Galietta, A.S. Verkman,Thiazolidinone CFTR inhibitor identifiedby high-throughput screening blockscholera toxin-induced intestinal fluidsecretion, J. Clin. Invest. 2002, 110,1651-1658.
11. T.J.F. Nieland, M. Penman, L. Dori,M. Krieger, T. Kirchhausen, Discoveryof chemical inhibitors of the selectivetransfer of lipids mediated by the HDLreceptor SR-BI. Proc. Natl. Acad. Sci. USA2002, 99, 15422-15427.
12. J.K. Chen, J. Taipale, K.E. Young,T. Maiti, P.A. Beachy, Small moleculemodulation of smoothened activity. Proc.Natl. Acad. Sci. USA 2002, 99,14071-14076.
13. T. Ma, L. Vetrivel, H. Yang,N. Pedemonte, O. Zegarra-Moran,L.J.V. Galietta, A.S. Verkman,High-affinity activators of cystic fibrosistransmembrane conductance regulator(CFTR) chloride conductance identifiedby high-throughput screening, J. Biol.Chem. 2002, 277, 37235-37241.
14. T.A. Sohn, R. Bansal, G.H. Su,K.M. Murphy, S.E. Kern, Highthroughputmeasurement of the Tp53response to anticancer drugs and randomcompounds using a stably integrated.Carcinogenesis 2002, 23, 949-957.
15. A. Cheung, J.A. Dantzig, S. Hollingworth, S.M. Baylor, Y.E. Goldman, T.J. Mitchison, A.F. Straight, A small-molecule inhibitor of skeletal muscle myosin II. Nat. Cell Bio. 2002, 4, 83-84.
16. R.V. Kondratov, P.G. Komarov, Y. Becker, A. Ewenson, A. Gudkov, Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. Proc. Natl. Acad. Sci. USA 2001, 98, 14078-14083.
17. R.T. Peterson, J.D. Mably, J. Chen, M.C. Fishman, Convergence of distinct pathways to heart patterning revealed by the small molecule concentramide and the mutation heart-and-soul. Curr. Biol.2001, 11, 1481-1491.
18. T.A. Sohn, G.H. Su, B. Ryu, C.J. Yeo, S.E. Kern, High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells. Annals of Surgery 2001, 233, 696-703.
19. C.M. Grozinger, E.D. Chao, H.E. Blackwell, D. Moazed, S.L. Schreiber, Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening, J. Biol. Chem. 2001, 276, 38837-38843.
20. A. Degterev, A. Lugovskoy, M. Cardone, B. Mulley, G. Wagner, T. Mitchison, J. Yuan, Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat. Cell Biol. 2001, 3, 173-182.
21. R. Peterson, B.A. Link, J.E. Dowling, S.L. Schreiber, Small molecule developmental screens reveal the logic and timing of vertebrate development.Proc. Natl. Acad. Sci. USA 2000, 97, 12965-12969.
22. T. Kim, T.Y. Kim, W.G. Lee, J. Yim, T.K. Kim, Signaling pathways to the assembly of an interferon-B enhanceosome, J. Biol. Chem. 2000, 275, 16910-16917.
23. G.H. Su, A.S. Taylor, R. Byungwoo, S.E. Kern, A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. 2000, 60, 3137-3142.
24. T.U. Mayer, T.M. Kapoor, S.J. Haggarty, R.W. King, S.L. Screiber, T.J. Mitchison, Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999, 286, 971-974.
25. P.G. Komarov, E.A. Komarova, R.V. Kondratov, K. Christov-Tselkov, J.S. Coon, M.V. Chernov, A.V. Gudkov, A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285, 1733-1337.
26. B.R. Stockwell, J.S. Hardwick, J.K. Tong, S.L. Schreiber, Chemical genetic and genomic approaches reveal a role for copper in specific gene activation, J. Amer. Chem. Soc. 1999, 121, 10662- 10663.
27. A.F. Straight, A. Cheung, J. Limouze, I. Chen, N.J. Westwood, J.R. Sellers, T.J. Mitchison, Dissecting temporal and spatial control of cytokines with a myosin II inhibitor. Science 2003, 299, 1743-1747.
28. G. Schneider, Trends in virtual combinatorial library design. Curr. Med.Chem. 2002, 9, 2095-2101.
29. W.P. Walters, M.T. Stahl, M.A. Murcko, Virtual screening - an overview. Drug Disc. Today 1998, 3, 160-178.
30. V. Gillet, Background theory of molecular diversity Mol. Diversity Drug Dis. 1999, 43-65.
31. R.S. Pearlman, K.M. Smith, Software for chemical diversity in the context of accelerated drug discovery, Drugs of the Future 1998, 23, 885-895.
32. J.S. Mason, I. Morize, P.R. Menard, D.L. Cheney, C. Hulme, R.F. Labaudiniere, New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures J. Med. Chem.1999, 42, 3251-3264.
33. A.B. Smith III, D.A. Favor, P.A. Sprengeler, M.C. Guzman, P.J. Carroll, G.T. Furst, R. Hirschmann, Molecular modeling, synthesis, and structures of N-methylated 3,5-linked pyrrolin-4-ones: toward the creation of a privileged nonpeptide scaffold. Bioorg. Med. Chem. 1999, 7, 9-22.
34. C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.Adv. Drug Del. Rev. 1997, 23, 3-25.
35. M.M. Hann, A.R. Leach, G. Harper, Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
36. D.A. Horton, G.T. Bourne, M.L. Smythe, The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem. Rev.2003, 103, 893-930.
37. A.A. Patchett, R.P. Nargund, Privileged structures: an update. Ann.Reports Med. Chem. 2000, 35, 289-298.
38. T.R. Webb, D. Lvovskiy, M.C. Heinrich, J.W.H. Yee, Discovery of novel inhibitors of tyrosine kinases.Abstracts, American Chemical Society (2001), 221st MEDI-228.
39. G.R. Marshall, Peptide interactions with G-protein coupled receptors.Biopolymers. 2001, 60, 246-277.
40. R.M. Campbell, C.G. Scanes, Evolution of the growth hormone-releasing factor (GRF) family of peptides. Growth Regul.1992, 2, 175-191.
41. V.J. Hruby, G. Han, M.E. Hadley, Design and bioactivities of melanotropic peptide agonist and antagonists: design based on a conformationally constrained somatostatin template. Lett. Pept. Sci.1998, 5, 117-120.
42. J.B. Ball, P.R. Alewood, Conformational constraints: nonpeptide ß-turn mimics, J. Mol. Rec. 1990, 2, 55-64.
43. G.L. Olson, D.R. Bolin, M.P. Bonner, M. Bos, C.M. Cook, D. Fry, B.J. Graves, M. Hatada, D.E. Hill, M. Kahn, V.S. Madison, V.K. Rusiecki, R. Sarabu, J. Sepinwall, G.P. Vincent, M.E. Voss, Concepts and progress in the development of peptide mimetics, J. Med. Chem. 1993, 21, 3041-3049.
44. A.E.P. Adang, P.H.H. Hermkens, J.T.M. Linders, H.C.J. Ottenheijm, C.J. van Staveren, Case histories of peptidomimetics: progression from peptides to drugs. Recl. Trav. Chem.Pays-Bas 1994, 113, 63-78.
45. D.S. Kemp, Peptidomimetics and the template approach to nucleation of betasheets and alpha-helices in peptides.Trends Biotechnol. 1990, 8, 249-255.
46. T. Sasaki, M. Lieberman, Protein mimetics, in Comprehensive Supramolecular Chemistry, Y. Murakami (Ed.), Pergamon: Oxford 1996, Vol. 4, 193-242.
47. V.J. Hruby, P.M. Balse, Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads. Curr. Med. Chem. 2000, 7, 945-970.
48. C.S.C. Wu, A. Hachimori, J.T. Yang, Lipid-induced ordered conformation of some peptide hormones and bioactive oligopeptides: predominance of the helix over the beta-form. Biochemistry 1982, 21, 4556-4562.
49. J.S. Nowick, M. Pairish, I.Q. Lee, D.L. Holmes, J.W. Ziller, An extended ß-strand mimic for a larger artificial ß-sheet, J. Am. Chem. Soc. 1997, 119, 5413-5424.
50. C. Nguyen, J.L. Teo, A. Matsuda, M. Eguchi, E.Y. Chi, W.R. Henderson Jr., M. Kahn, Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma. Proc. Natl.Acad. Sci. USA 2003, 100, 1169-1173.
51. A.G. Tzakos, A.M. Bonvin, A. Troganis, P. Cordopatis, M.L. Amzel, I.P. Gerothanassis, N.A. van Nuland, On the molecular basis of the recognition of angiotensin II (AII): NMR structure of AII in solution compared with the X-ray structure of AII bound to the mAb Fab131, Eur. J. Biochem. 2003, 270, 849-860.
52. M. Miskolzie, L. Gera, J.M. Stewart, G. Kotovych, The importance of the N-terminal beta-turn in bradykinin antagonists, J. Biomol. Struct. Dyn. 2000, 18, 249-260.
53. C. Giragossian, E.E. Sugg, J.R. Szewczyk, D.F. Mierke, Intermolecular interactions between peptidic and nonpeptidic agonists and the third extracellular loop of the cholecystokinin 1 receptor, J. Med. Chem.2003, 46, 3476-3482.
54. S.Z. Li, J.H. Lee, W. Lee, C.J. Yoon, J.H. Baik, S.K. Lim, Type I beta-turn conformation is important for biological activity of the melanocyte-stimulating hormone analogues, Eur. J. Biochem.1999, 265, 430-440.
55. L. Abrous, J. Hynes Jr., S.R. Friedrich, A.B. Smith III, R. Hirschmann, Design and synthesis of novel scaffolds for drug discovery: hybrids of ß-d-glucose with 1,2,3,4-tetrahydrobenzo[e] [1,4]diazepin-5- one, the corresponding 1-oxazepine, and 2-and 4-pyridyldiazepines, Org. Lett. 2001, 3, 1089-1092.
56. J. Rivier, S.L. Lahrichi, J. Gulyas, J. Erchegyi, S.C. Koerber, A.G. Craig, A. Corrigan, C. Rivier, W. Vale, Minimal-size, constrained corticotropinreleasing factor agonists with i-(i + 3) Glu-Lys and Lys-Glu bridges, J. Med.Chem. 1998, 41, 2614-2620.
57. S. Maretto, S. Mammi, E. Bissacco, E. Peggion, A. Bisello, M. Rosenblatt, M. Chorev, D.F. Mierke, Mono- and bicyclic analogs of parathyroid hormonerelated protein. 2. Conformational analysis of antagonists by CD, NMR, and distance geometry calculations, Biochemistry 1997, 36, 3300-3307.
58. D.A. Kirby, J.H. Boublik, J.E. Rivier, Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions, J. Med.Chem. 1993, 36, 3802-3808.
59. K. Haghjoo, P.W. Cash, R.S. Farid, B.R. Komisaruk, F. Jordan, S.S. Pochapsky, Solution structure of vasoactive intestinal polypeptide (11-28)- NH2, a fragment with analgesic properties. Pept. Res. 1996, 9, 327-331.
60. M. Qabar, J. Urban, C. Sia, M. Klein, M. Kahn, Peptide secondary structure mimetics: applications to vaccines and pharmaceuticals. Farmaco 1996, 51, 87-96.
61. S.L. Garland, P.M. Dean, Design criteria for molecular mimics of fragments of the beta-turn. 1. C alpha atom analysis, J. Comput.-Aided Mol. Des.1999, 13, 469-483.
62. S.L. Garland, P.M. Dean, Design criteria for molecular mimics of fragments of the beta-turn. 2. C alpha- C beta bond vector analysis, J. Comput.- Aided Mol. Des. 1999, 13, 485-498.
63. D. Chianelli, Y.-C. Kim, D. Lvovskiy, T.R. Webb, Application of a novel design paradigm to generate general nonpeptide combinatorial scaffolds mimicking beta turns: synthesis of ligands for somatostatin receptors, Bioorg. and Med. Chem.2003, 11, 5059-5068.
64. Measurements on MM2-minimized structures were done with CAChe for Windows and with Chem-3D Pro.
65. I. Im, T.R. Webb, Y.D. Gong, J.-I. Kim, J.-C. Kim, Solid phase synthesis of tetrahydro-1,4-benzodiazepine-2-one derivatives as a beta-turn peptidomimic library, J. Comb. Chem. 2004, 6, 207-213.
66. G. Müller, G. Hessler, H.Y. Decornez, Are beta-turn mimetics mimics of betaturns? Angew. Chem., Int. Ed. 2000, 39, 894-896.
67. D.C. Horwell, W. Howson, W.P. Nolan, G.S. Ratcliffe, D.C. Rees, H.M.G. Willems, The design of dipeptide helical mimetics.I. The synthesis of 1,6-disubstituted indanes, Tetrahedron 1995, 51, 203-216.
68. D.C. Horwell, W. Howson, G.S. Ratcliffe, H.M.G. Willems, The design of dipeptide helical mimetics: the synthesis, tachykinin receptor affinity and conformational analysis of 1,1,6-trisubstituted indanes, Bioorg.and Med. Chem. 1996, 4, 33-42.
69. B.P. Orner, J.T. Ernst, A.D. Hamilton, Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alphahelix, J. Am. Chem. Soc. 2001, 123, 5382-5383.
70. D.S. Kemp, T.P. Curran, J.G. Boyd, T.J. Allen, Studies of N-terminal templates for alpha-helix formation: synthesis and conformational analysis of peptide conjugates of (2S,5S,8S,11S)- 1-acetyl-1,4-diaza-3-keto-5-carboxy-10- thiatricyclo[2.8.1.04,8]tridecane (Ac-Hel1- OH), J. Org. Chem. 1991, 56, 6683-6697.
71. G. Mer, E. Kellenberger, J.F. Lefevre, Alpha-helix mimicry of a beta-turn, J. Mol. Biol. 1998, 281, 235-240.